

Appl. No. : 01,797  
Filed : July 23, 1998

B4  
cont

pharmaceutically acceptable carrier to reduce the expression and/or effects resulting from expression of said polynucleotide encoding or said peptide, said inhibitor being directed against [said]the isolated polynuceotide, or [an] isolated peptide of Claim 35[, or a receptor or receptors of said isolated peptide].

#### REMARKS

Applicants acknowledge receipt of the communication mailed from the Patent and Trademark Office on December 22, 1999 (Paper No. 6). Applicants have elected for initial prosecution Group I Claims 35-42 and 47 as required in the Restriction Requirement of December 22, 1999. Claims 43-46 and 53-56 are cancelled as being drawn to a non-elected invention. This election is made without traverse.

#### Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned attorney at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 24 Jan. 2000

By: Daniel Altman  
Daniel E. Altman  
Registration No. 34,115  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 760-0404

H:\DOCS\VAHV\AH-1937.DOC  
012000